Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients

Clin Transl Med. 2024 Apr;14(4):e1617. doi: 10.1002/ctm2.1617.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal* / pharmacology
  • Antibodies, Monoclonal* / therapeutic use
  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use
  • CD4-Positive T-Lymphocytes* / drug effects
  • CD4-Positive T-Lymphocytes* / immunology
  • CD4-Positive T-Lymphocytes* / metabolism
  • Female
  • Humans
  • Intraepithelial Lymphocytes / drug effects
  • Intraepithelial Lymphocytes / immunology
  • Intraepithelial Lymphocytes / metabolism
  • Middle Aged
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / immunology

Substances

  • durvalumab
  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological